

# Tardive syndrome: An update and mini-review from the perspective of phenomenology

Chun-Yu Chen<sup>a</sup>, Han-Lin Chiang<sup>b</sup>, Jong-Ling Fuh<sup>b,c,d,\*</sup>

<sup>a</sup>Department of Medicine, Taipei Veterans General Hospital Yuli Branch, Hualian, Taiwan, ROC; <sup>b</sup>Division of General Neurology, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; <sup>c</sup>Faculty of Medicine, National Yang-Ming University, School of Medicine, Taipei, Taiwan, ROC; <sup>d</sup>Brain Research Center, National Yang-Ming University, Taipei, Taiwan, ROC

**Abstract:** Tardive syndrome (TS) is a group of movement disorders caused by the long-term use of dopamine receptor blocking agents. The phenotypic presentation of TS is diverse, ranging from the most well-characterized symptom of tardive dyskinesia to other symptoms, including dystonia, akathisia, myoclonus, parkinsonism, tremor, and tics. These tardive symptoms are distinct not only in their phenomenology but also in their clinical outcomes. However, our knowledge of the pathophysiology and management of TS is almost exclusively based on tardive dyskinesia. First-generation antipsychotics have a higher risk of inducing TS and have largely been replaced by second-generation antipsychotics with a lower risk of TS. However, patients with off-label use of second-generation antipsychotics are still at risk of developing TS. Thus, the management of TS remains a challenging and important issue for physicians. In this review, we update the information on the epidemiology, phenomenology, and treatment of TS from the perspective of the specific form of TS.

**Keywords:** Antipsychotic; Dopamine receptor blocking agents; Tardive dyskinesia; Tardive syndrome

## 1. INTRODUCTION

Tardive syndrome (TS) is a constellation of late-onset and usually persistent involuntary movements caused by long-term dopamine receptor blocking agent (DRBA) exposure. The name “tardive” comes from the Latin word “*Tardus*”, implicating the late-onset feature of the disorder. The phenomenologies seen in TS include dyskinesia, stereotypy, dystonia, akathisia, myoclonus, tremor, tics, and pain (Table 1).<sup>1–3</sup> Among these, tardive dyskinesia (TD), characterized by stereotyped, involuntary movements of the face, mouth, and tongue (oral-buccal-lingual dyskinesia), with possible involvement of the extremities, was the first identified and the most common presentation of TS.<sup>4</sup> To date, most of the studies on TS have focused on TD, with only a few reports related to other phenomenologies. Therefore, in this review, we aim to summarize and update the pathophysiology, clinical presentations, and management of TS based on different phenomenologies.

## 2. PATHOPHYSIOLOGY

The most popular theory is dopamine receptor hypersensitivity. The pathophysiology of TD is proposed to result from chronic blockade of dopamine receptors (particularly D2 and possibly D3 receptors), which induces upregulation of D2 receptors

and causes postsynaptic dopamine receptor hypersensitivity (Fig. 1).<sup>5,6</sup> D2 receptors are inhibitory receptors expressed on striatal medium spiny neurons that inhibit the inhibitory indirect pathway, so their hypersensitivity produces hyperkinetic movements.<sup>5</sup> In addition to dopamine receptors, rodent studies have shown that serotonin receptors (5-HT<sub>2</sub> receptors, in particular), which are widely distributed in the striatum, interact with dopaminergic neurotransmission, and their blockade reduces D2 receptor upregulation.<sup>6,7</sup> Additionally, the 5-HT<sub>2</sub> gene has been shown to be associated with susceptibility to TD in schizophrenic patients.<sup>8</sup> This has been proposed to be the mechanism by which second-generation antipsychotics, with a lower D2 receptor affinity but higher 5-HT<sub>2</sub> receptor affinity, have a lower risk of inducing TD than first-generation antipsychotics. However, D2 receptor hypersensitivity and upregulation cannot explain the persistence of symptoms, potentially lasting years, after discontinuation of DRBA because theoretically, in the absence of continuous blockade, dopamine receptors would be downregulated.

Striatal parvalbumin-containing, fast-spiking GABAergic interneurons synapse on medium-spiny neurons and regulate the balance between the direct and indirect pathways.<sup>5,6</sup> It has been proposed that chronic neuroleptic administration impairs the antioxidant system and increases dopamine turnover, which induces free radical formation and leads to neuronal damage and subsequent degeneration of GABAergic interneurons, leading to an imbalance between the direct and indirect pathways.<sup>6,9,10</sup> However, the phenomenological diversity of TS and the exact pathomechanism by which antipsychotics produce dystonia in some patients and dyskinesia in others remain elusive.

## 3. TARDIVE SYNDROME

### 3.1. Prevalence and risk factors

A recent meta-analysis included 41 studies from 2000 to 2015, and the global mean prevalence of TD in patients taking typical and/or atypical antipsychotics was 25.3% (Table 2).<sup>11</sup> The rate

\*Address correspondence. Dr. Jong-Ling Fuh, Division of General Neurology, Neurological Institute, Taipei Veterans General Hospital, 201, Section 2, Shi-Pai Road, Taipei 112, Taiwan, ROC. E-mail address: jlfuh@vghtpe.gov.tw (J.-L. Fuh).

Conflicts of interest: The authors declare that they have no conflicts of interest related to the subject matter or materials discussed in this article.

Journal of Chinese Medical Association. (2020) 83: 1059-1065.

Received September 1, 2020; accepted September 1, 2020.

doi: 10.1097/JCMA.0000000000000435.

Copyright © 2020, the Chinese Medical Association. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

**Table 1**  
Phenomenology of tardive syndrome

Phenomenology	Presentation
Dyskinesia	This classically manifests as oro-buccal-lingual dyskinesia, which involves stereotyped, involuntary movements of the tongue (protrusion or twisting), lips (smacking or puckering), and jaw (chewing). Involvement of the extremities, trunk or respiratory muscles is possible. Limb movements usually occur in distal segments as piano-playing movements or foot tapping. Truncal movements are rocking back and forth. When respiratory muscles are affected, it creates loud breathing, hyperventilation, or distorted speech. TD can be suppressed by voluntary action.
Dystonia	This tends to emerge focally and develops into a segmental or generalized form over time. It usually co-occurs with TD. The face and neck are the most commonly involved site, followed by the arms, trunk, and then legs. Cranial dystonia is typically blepharospasm. Cervical dystonia is primarily retrocollis. Truncal dystonia is commonly opisthotonic posturing. The appearance of dystonia is indistinguishable from idiopathic dystonia.
Akathisia	This is characterized by a feeling of inner restlessness and inability to remain still. The manifestations are typically body rocking and lower body involvement, including rocking from leg to leg, marching in place, or crossing and uncrossing legs.
Myoclonus	This is typically postural and predominantly involves the arms and hands.
Tremor	This can be kinetic, postural, or resting. It usually has a high amplitude, a frequency of 3-5 Hz, and most importantly, no parkinsonian signs.
Tics	These are indistinguishable from Tourette's syndrome by phenomenology.
Pain	This is chronic pain in the mouth and tongue or genital regions.

TD = tardive dyskinesia.

is highest with current typical antipsychotic treatment (30%), followed by current atypical antipsychotic treatment (20.7%), and lowest in patients never exposed to typical antipsychotics (7.7%).<sup>11</sup> In a prospective cohort study that followed 362 chronic psychiatric, TD-free outpatients for 5 years, the predicted risk of developing TD with typical neuroleptics increases with duration of exposure, from 32% for 5 years, 57% for 15 years, and 68% after 25 years.<sup>12</sup> According to the most recent meta-analysis, the annual incidence of TS is 3% in adults taking atypical antipsychotics and 7.7% in those taking typical antipsychotics.<sup>13</sup>

The nonmodifiable risk factors for TD include older age, female sex, white or African descent, genetic variants involving antipsychotic metabolism and dopamine function, longer disease duration, and preexisting mood disorders.<sup>14,15</sup> Older age has been consistently identified as a risk factor for TD, with a 2- to 5-fold increase in incidence in elderly adults compared with


younger adults.<sup>14</sup> Females had a higher risk for TD (prevalence: female:male, 26.6% vs 21.6%), and their symptoms tended to be more severe.<sup>16</sup> In terms of ethnicity, the risk for TD was lowest in Asians and highest in African Americans.<sup>17</sup> Individuals with polymorphisms in *CYP2D6* (antipsychotic clearance), *COMT* (dopamine metabolism), *VMAT2* (dopamine packaging), and *DRD2* (dopamine receptor functioning) have a greater susceptibility to TD.<sup>14</sup> The higher risk of TD in patients with longer disease duration may be a combined effect of exposure to first-generation antipsychotics, cumulative antipsychotic dose or older age.<sup>14</sup> The relationship between pre-existing mood disorders and TD comes from an older literature when patients were usually treated with first-generation antipsychotics.<sup>18</sup>

The modifiable risk factors for TD include first-generation antipsychotics, duration and dose of DRBA exposure, acute motor syndrome, and alcohol abuse.<sup>19</sup> It has been consistently shown that the annual incidence of TD is significantly lower in patients taking second-generation antipsychotics (0.8%-3%) than in those taking first-generation antipsychotics (5.4%-7.7%).<sup>13</sup> Longer duration of treatment and higher doses of antipsychotics have been associated with a higher risk of TD.<sup>19</sup> If patients have acute extrapyramidal symptoms, including parkinsonism, dystonia, akathisia, and subtle dyskinetic movements, after taking antipsychotics, they are expected to have a higher chance of developing TD.<sup>20,21</sup> Alcohol and substance abuse have been associated with an increased risk for TD in schizophrenic patients taking antipsychotics.<sup>22,23</sup>

### 3.2. Clinical course and phenomenology

TD is characterized by oral-buccal-lingual dyskinesia (OBLD) (Table 1). OBLD was previously classified as tardive stereotypy.<sup>1</sup> However, this movement lacks distractibility, which is a core feature of stereotypy. The current consensus defined tardive stereotypy as a seemingly purposeful movement pattern that is repetitive, coordinated, and distractible.<sup>1,6</sup> Its usual presentation is rocking, crossing legs, and rubbing hands when not feeling restless.<sup>24</sup>

The onset of TD typically develops after 1-2 years of DRBA exposure, but the exposure duration can be as short as 3 months.<sup>6,25</sup> The onset is insidious and plateaus over days to weeks. However, waxing and waning of symptom severity during the disease course is not uncommon.<sup>3,6</sup> In the majority of patients, TD usually persists for years or decades, even after removal of the offending drug.<sup>6</sup> Complete or partial remission can occur in some patients after several years with or without discontinuation of the offending drug. The reported annual spontaneous remission rate (without discontinuation of DRBAs)



**Fig. 1** Pathomechanism of tardive dyskinesia. MSN = median spiny neuron.

**Table 2**  
Prevalence of tardive syndrome

Phenomenology	Year	Patient number	Prevalence	Reference
Dyskinesia	2000-2015	5103	Current second-generation antipsychotics: 20.7%	11
	2000-2015	5062	Current first-generation antipsychotics: 30.0%	11
	2000-2015	346	First-generation antipsychotic naïve: 7.2%	11
	2000-2015	11 493	Pooled prevalence: 25.3%	11
Dystonia	1989	917	Psychiatric inpatients: 0.4%	66
		200	Psychiatric inpatients: 4.0%	67
		125	Particularly high prevalence using a more inclusive criteria: 21%	68
Akathisia		842	Psychiatric inpatients: 3.2%	69
		123	Elderly patients: 32.5%	70
Myoclonus		100	Patients with tardive syndrome: 1.0%	71
		60	Psychiatric inpatients: 38%	61
Tremor		123	Psychiatric outpatients: 2.4%	63
		100	Patients with tardive syndrome: 30%	71
Tics			41 cases reported in 38 case reports	62
Pain			11 cases reported in a case series	64

was 2.5%.<sup>26,27</sup> However, continued use of antipsychotics may suppress dyskinesia and hinder determination of the accuracy of the spontaneous remission rate. Ethnicity seems to play a role in determining prognosis. African Americans are less likely to improve than European Americans.<sup>28</sup> Older age and nonorofacial TD are predictors for chronic persistent TD.<sup>29</sup>

### 3.3. Treatment

Before initiating pharmacological treatments for TD, there are generally two approaches to reduce TD: withdrawal of the offending antipsychotics or switching from a first-generation antipsychotic to a second-generation antipsychotic with lower D2 receptor affinity. Withdrawal is usually not clinically feasible for patients with schizophrenia because of high rates of symptom worsening or relapse.<sup>30</sup> The switching approach, according to the American Academy of Neurology guideline in 2013, is not recommended because the alleviating effect supported by a number of open-label trials is contradicted by the negative finding in a single-blind crossover study.<sup>31</sup> However, a recent meta-analysis showed beneficial effects in reducing TD severity by switching from typical antipsychotics to clozapine.<sup>32</sup> Therefore, switching can be considered in clinical settings when medication withdrawal is not possible (Table 3).<sup>33,34</sup> Clozapine is the first second-generation antipsychotic and has been extensively studied. Its therapeutic effects in reducing TD are primarily based on the lowest D2 receptor affinity among antipsychotics, with additional potential mechanisms involving antiserotonergic (5HT<sub>2A</sub> and 5HT<sub>1C</sub>) and anticholinergic effects and less activity at nigrostriatal dopaminergic neurons.<sup>35,36</sup> Quetiapine, with high affinity for 5-HT<sub>2A</sub> and lower affinity for D2 receptors, is a reasonable alternative.<sup>33,36</sup> Improvement of TD by switching to risperidone or olanzapine for several weeks has been observed in some trials.<sup>31</sup> However, there are concerns with their use beyond 48 weeks because both risperidone and olanzapine have been known to show dose-dependent increases in the risk of developing extrapyramidal side effects.<sup>31,36</sup>

Among the pharmacological agents, selective vesicular monoamine transporter 2 (VMAT2) inhibitors are the most effective and the only FDA approved medication to treat TD (Table 3). Tetrabenazine was the first VMAT2 inhibitor and was approved for treating Huntington chorea.<sup>37</sup> The beneficial effects of tetrabenazine on TD has consistently been found in several randomized controlled trials (RCTs), and the improvement can be a greater than 50% reduction in severity that is achieved in at least 50% of patients.<sup>38,39</sup> However, the most

common side effects are drowsiness and parkinsonism.<sup>33</sup> In 2017, the FDA approved two newer VMAT2 inhibitors, valbenazine and deutetrabenazine, for treating TD. Two RCTs demonstrated dose-dependent reductions in dyskinesia severity in patients taking valbenazine evidenced by a much or very much improved global impression of change in approximately 60% of patients and a mean reduction in Abnormal Involuntary Movement Scale (AIMS) scores of 2.6 points.<sup>40,41</sup> The long half-life of valbenazine allows once daily dosing and better tolerability; only approximately 10% of participants had mild adverse effects, which included fatigue, akathisia, or dry mouth.<sup>40,41</sup> There were also two randomized RCTs evaluating the treatment effect of deutetrabenazine that revealed a significant treatment difference of 1.4 to 1.9 points in the AIMS score,<sup>42,43</sup> with a slightly higher rate of headache as the most common side effect.<sup>43</sup> Thus, valbenazine and deutetrabenazine are recommended as the first-line treatment for TD.<sup>33,44</sup>

Clonazepam should be used with caution because of its side effects of sedation and dependence (Table 3),<sup>33</sup> and patients with dystonic symptoms may benefit more.<sup>38</sup> Vitamin B6 and pyridoxal-5'-phosphate (active form of vitamin B6) are recommended only for short-term use because long-term treatment may cause sensory neuropathy (Table 3).<sup>33</sup> The improvement by amantadine was significant but small (approximately 15%),<sup>31</sup> and amantadine can be considered if more established agents fail or are contraindicated (Table 3).<sup>33,38</sup> If all pharmacological treatments fail, deep brain stimulation may be the last resort (Table 3). The target in most cases is the bilateral posteroventral globus pallidus internus and, in some cases, the subthalamic nucleus. The beneficial effect of pallidal deep brain stimulation has been supported by a number of case reports/series and two randomized trials, with mean improvements in AIMS scores of 38% to 63%.<sup>33,45,46</sup>

## 4. TARDIVE DYSTONIA

### 4.1. Prevalence and risk factors

The reported prevalence of tardive dystonia is variable, probably due to different assessment methods. The prevalence generally falls between 0.4% and 5% but can be as high as 21% if the criteria used are more inclusive (Table 2).<sup>47</sup> Compared with TD, tardive dystonia has been associated with a younger age of onset with a slight male predominance.<sup>48</sup> The onset age tends to be younger in male patients than female patients.<sup>49</sup>

**Table 3**  
**Treatment for tardive syndrome**

Phenomenology	Treatment (maximum daily dose)	Mechanism of action	Comments
All	Switching from first-generation antipsychotics to clozapine <sup>33</sup>	Low D2 receptor affinity	Several RCTs, all done in TD, showed significant reduction in TD scores, particularly in moderate to severe TD; the strategy can be applied to other tardive movement disorders
Dyskinesia	Tetrabenazine (150 mg) <sup>33, 44</sup>	VMAT2 inhibition	FDA approval for Huntington disease, off-label use for TD; risk of parkinsonism
	Valbenazine (80 mg) <sup>33, 44</sup>		The only two FDA approved drugs for TD with a much lower risk of inducing parkinsonism but much higher cost
	Deutetrabenazine (48 mg) <sup>33, 44</sup>		
	Clonazepam (4.5 mg) <sup>44, 72</sup>	GABAergic (GABA <sub>A</sub> receptor)	One RCT showed a 37% improvement in TD scores; risk of dependence; greater benefit on dystonic symptoms
	Vitamin B6, pyridoxine (1200 mg) <sup>44, 72</sup>	Antioxidant	Two RCTs showed significant improvements in TD scores; risk of sensory neuropathy with long-term use
	Ginkgo biloba (240 mg) <sup>44, 72</sup>		One RCT showed 51.3% of patients achieving ≥30% reduction in TD scores
	Vitamin E (1600 IU) <sup>31, 33</sup>		Several RCTs with conflicting findings (no improvement or 24%-47% improvement on TD scores); may protect against deterioration of TD
	Levetiracetam (3000 mg) <sup>31, 72</sup>	SV2A inhibition (inhibition of synaptic vesicle release)	One RCT and several open-label trials showed up to 43.5% improvement in TD scores, but high dropout rate because of psychiatric deterioration
	Amantadine (400 mg) <sup>33, 44</sup>	Weak NMDA receptor inhibition	Several RCTs showed 15-21.8% improvement in TD scores; risk of hallucination
	Deep brain stimulation <sup>45, 46</sup>	Stimulation of globus pallidus interna	One uncontrolled trial and one RCT showed 38%-60% improvement in TD scores; after failure of medical treatment with stable psychiatric condition
	Botulinum toxin <sup>52</sup>	Decrease release of acetylcholine	One uncontrolled trial showed marked or moderate improvement in 85% of patients; for focal dystonia
	Dystonia	Trihexyphenidyl (30 mg) <sup>49</sup>	Acetylcholine receptor inhibition
Clonazepam (6 mg) <sup>49</sup>		GABAergic (GABA <sub>A</sub> receptor)	Retrospective studies showed mild improvement in 53% of patients; risk of dependence
Baclofen (40 mg) <sup>53, 73</sup>		Activation of GABA <sub>B</sub> receptor	Retrospective studies showed mild improvement in 56% of patients; can be given intrathecally for severe cases
Tetrabenazine (200 mg) <sup>49</sup>		Vesicular monoamine transporter 2 inhibition	Retrospective studies showed some improvement in 53% of patients; risk of parkinsonism
	Deep brain stimulation <sup>45, 46</sup>	Stimulation of globus pallidus interna	One uncontrolled trial and one RCT showed 41.5%-71% improvements in dystonia scores; after failure of medical treatment with stable psychiatric condition
	Propranolol (80 mg) <sup>56, 57</sup>	β-1-adrenergic receptor inhibition	Case reports showed contradictory effects; other medication tried in case reports with contradictory effects: anticholinergics, clonazepam, lorazepam
Akathisia	Tetrabenazine (175 mg) <sup>56</sup>	VMAT2 inhibition	Case reports showed marked improvement in 50% of patients; risk of parkinsonism
Myoclonus	Clonazepam (3 mg) <sup>61</sup>	GABAergic (GABA <sub>A</sub> receptor)	One retrospective study showed reduced frequency and amplitude of myoclonus in all patients; risk of dependence
	Tetrabenazine (125 mg) <sup>65</sup>	VMAT2 inhibition	Case reports showed improvement in all patients; risk of parkinsonism
Tremor	Clonazepam (3 mg) <sup>62</sup>	GABAergic (GABA <sub>A</sub> receptor)	Case reports showed some improvements in two patients; risk of dependence
Tics	Clonidine (0.8 mg) <sup>62</sup>	Activation of α <sub>2</sub> -adrenergic receptor	Case reports showed some improvements in two patients
	Discontinuation of offending drugs <sup>62</sup>		Case reports showed full recovery in 7 out of 9 cases
	Pain	Tetrabenazine (75 mg) <sup>64</sup>	VMAT2 inhibition

FDA = Food and Drug Administration; RCT = randomized controlled trial; TD = tardive dyskinesia; VMAT2 = vesicular monoamine transporter 2.

## 4.2. Clinical course and phenomenology

Tardive dystonia often begins after a shorter period of exposure to antipsychotics than does TD, with a mean duration of exposure from 3.3 to 6.6 years vs 5.4 to 15.4 years for TD.<sup>47</sup> It tends to begin with focal dystonia and may evolve to a segmental or even generalized form over time (Table 1). The most frequently involved muscles are cervical and cranial muscles (approximately two-thirds of patients).<sup>47</sup> When blepharospasm and oromandibular dystonia coexist, it can be termed tardive Meige syndrome.<sup>50</sup> In a long-term follow-up study (Table 2), it was observed that patients with tardive dystonia more frequently had retrocollis and antecollis and less torticollis.<sup>49</sup> Tardive dystonia and TD often coexist (84% in one series).<sup>47</sup> In comparison to TD, tardive dystonia has a more unfavorable prognosis: the remission rate ranges from 7.5% to 14% after 3.1-8.5 years.<sup>49</sup> The removal of all offending drugs permanently or only for a certain period of time increases the chance of remission. The duration of antipsychotic exposure is also important. Patients with less than 10 years of exposure are five times more likely to remit than those exposed for more than 10 years.<sup>49, 51</sup>

## 4.3. Treatment

Local injection of botulinum toxin can be the first treatment of choice for focal dystonias, particularly blepharospasm and torticollis (Table 3).<sup>52, 53</sup> Anticholinergics and dopamine depletors (reserpine or tetrabenazine) are other options (Table 3).<sup>53, 54</sup> If pharmacological therapies fail, deep brain stimulation targeting the globus pallidus internus should be considered (Table 3). The beneficial effect of pallidal deep brain stimulation has been supported by a number of case reports/series and two randomized trials, revealing a range of improvements from 41.5% to 71%.<sup>33, 45, 46</sup>

## 5. TARDIVE AKATHISIA

### 5.1. Prevalence and risk factors

The reported prevalence for tardive akathisia is from 20% to 30% (Table 2).<sup>55</sup> However, tardive akathisia may be overlooked if limb movements are present in TD.<sup>55</sup> Compared with TD, patients with tardive akathisia are slightly younger.<sup>55</sup> Among older patients with tardive akathisia, females are more prevalent than males (1.9:1).<sup>56</sup>

## 5.2. Clinical course and phenomenology

Akathisia is a subjective feeling of restlessness, accompanied by motor presentations of an inability to stay still. Tardive akathisia primarily involves the lower body (Table 1).<sup>1</sup> According to an early report with 45 patients, almost all patients with tardive akathisia concurrently had typical TD (99%), and many had tardive dystonia (35%).<sup>56</sup> Patients with the coexistence of tardive akathisia and tardive dystonia had the earliest onset. Tardive akathisia most frequently affects the legs, followed by the trunk and then the arms.<sup>56</sup> Patients with well-controlled or remitted akathisia were exposed to DRBAs at a younger age and had their DRBAs discontinued at a younger age than those with persistent akathisia.<sup>56</sup>

## 5.3. Treatment

For tardive akathisia, withdrawal of offending antipsychotics can be tried, or they can be replaced by clozapine.<sup>57,58</sup> Propranolol, lorazepam, and anticholinergics have been effective based on case reports (Table 3).<sup>56,57</sup> Tetrabenazine was reported to be effective in 58% of 12 patients in a therapeutic trial (Table 3).<sup>56</sup>

## 6. OTHER TARDIVE MOVEMENT DISORDERS

### 6.1. Prevalence and risk factors

Epidemiological data on tardive myoclonus are limited, and isolated tardive myoclonus is rare.<sup>59,60</sup> A study found that 38% of patients with long-term antipsychotic exposure had postural myoclonus, although the majority also had other concomitant involuntary movements (Table 2).<sup>61</sup> Tardive tremor, tics and pain are rare.<sup>25,62</sup> The prevalence of tardive tremor was reported to be 2.4% in patients receiving antipsychotics (Table 2).<sup>63</sup> To date, only 41 cases of tardive Tourette-like syndrome have been reported.<sup>62</sup> Similarly, only one case series reported 11 patients with TD or tardive akathisia with oral or genital pain.<sup>64</sup>

A survey found that myoclonic patients were exposed to higher daily and cumulative doses of antipsychotics than nonmyoclonic patients.<sup>61</sup> According to a case series, 10 out of the 11 patients reported to have tardive pain were female.<sup>64</sup> There are no known risk factors for the development of tardive tremor and tics.

### 6.2. Clinical course and phenomenology

Tardive myoclonus is primarily postural and affects the arms and shoulders more frequently than other body parts.<sup>1,61</sup> Head and neck involvement was described in a single case report.<sup>60</sup> In general, the movements are not severe, and most patients are unaware of the movements.<sup>16</sup> Tardive tremor is either postural or resting, with a frequency of 3 to 5 Hz and high amplitude. It usually emerges after prolonged exposure to DRBAs and persists for an average of 6 years after their discontinuation.<sup>65</sup> Tremor can be a frequent manifestation of antipsychotic-induced parkinsonism, but tardive tremor differs by its persistence after discontinuation of the offending drugs and unresponsiveness to parkinsonian or essential tremor therapies.<sup>25</sup>

The main difference between tardive tics and Tourette's syndrome is the age of onset. Tourette's syndrome typically begins before the age of 15 years, whereas tardive tics begin at an older age.<sup>1</sup> For most patients, symptoms develop after months to years (up to 24 years) of DRBA exposure; in some patients, tics emerge within 2 weeks to 1 year after discontinuation of DRBA.<sup>62</sup> In a review involving 38 case reports and 41 patients, approximately 25% of the patients also had TD.<sup>62</sup> The prognosis is generally good: 17 out of 41 patients had full remission, and 11 had partial remission.<sup>62</sup>

Tardive pain is typically a burning or lacerating sensation in the mouth or pelvis.<sup>64</sup> The pain typically develops after 1-6 years of DRBA exposure.<sup>64</sup> Tests for pain, including gynecologic evaluations, dental examinations, and imaging studies, fail to find an

organic lesion. Tardive pain is always accompanied by tardive movement symptoms (dyskinesia, dystonia, or akathisia), so the diagnosis should not be made in the absence of a tardive movement disorder.<sup>24</sup>

### 6.3. Treatment

Benzodiazepines may be beneficial (clonazepam) for tardive myoclonus (Table 3).<sup>1</sup> Tardive tremor usually has a poor response to conventional antitremor therapy and may benefit from tetrabenazine (Table 3).<sup>65</sup> According to case reports, tardive tics can be improved in most cases by switching to second-generation antipsychotics (such as aripiprazole, clozapine, quetiapine, risperidone, or amisulpride), discontinuation of the offending drugs or treatment with clonazepam or clonidine (Table 3).<sup>62</sup> Finally, in a case series of patients with tardive pain, seven out of nine patients had marked improvement or even resolution of pain after treatment with reserpine and/or tetrabenazine (Table 3).<sup>64</sup>

In conclusion, TS leads to reduced quality of life and even disability but is inevitable for some patients who require long-term use of antipsychotics. Over the past decade, the most important advancement in treatment has been the development of valbenazine and deutetrabenazine, which provide favorable outcomes but fewer side effects than conventional tetrabenazine. On the contrary, the belief that second-generation antipsychotics may possess a lower risk of developing TS, which has not been consistently demonstrated, may promote their off-label use and can lead to an increased prevalence of TS. The best treatment for TS continues to be the prevention of its occurrence.

In conclusion, TS is diverse not only in its phenomenology but also in its clinical outcomes. The pathophysiology of the syndrome is still unclear and warrants further research. Future studies including patients with well-classified phenomenology may provide additional insights into the understanding of the disorder as well as treatment.

## ACKNOWLEDGMENTS

The study was supported in part by grants from the Ministry of Science and Technology of Taiwan (109-2314-B-075-052-MY2), Taipei Veterans General Hospital (V109C-061 and VGHUST109-V1-5-1), the Brain Research Center, National Yang-Ming University, from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education in Taiwan.

## REFERENCES

1. Aquino CC, Lang AE. Tardive dyskinesia syndromes: current concepts. *Parkinsonism Relat Disord* 2014;20(Suppl 1):S113-7.
2. Truong DD, Frei K. Setting the record straight: the nosology of tardive syndromes. *Parkinsonism Relat Disord* 2019;59:146-50.
3. Owens DC. Tardive dyskinesia update: the syndrome. *BJPsych Advances* 2019;25:57-69.
4. Kulenkampff C, Tarnow G. Ein eigentümliches syndrom im oralen bereich bei megaphenapplikation. *Nervenarzt* 1956;27:178-80.
5. Teo JT, Edwards MJ, Bhatia K. Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis. *Mov Disord* 2012;27:1205-15.
6. Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. *Tremor Other Hyperkinet Mov (N Y)* 2013;3.
7. Kusumi I, Takahashi Y, Suzuki K, Kameda K, Koyama T. Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5-HT2A receptors in the rat brain. *J Neural Transm (Vienna)* 2000;107:295-302.
8. Segman RH, Heresco-Levy U, Finkel B, Goltser T, Shalem R, Schlafman M, et al. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. *Mol Psychiatry* 2001;6:225-9.
9. Cho CH, Lee HJ. Oxidative stress and tardive dyskinesia: pharmacogenetic evidence. *Prog Neuropsychopharmacol Biol Psychiatry* 2013;46:207-13.

10. Lohr JB, Kuczenski R, Niculescu AB. Oxidative mechanisms and tardive dyskinesia. *CNS Drugs* 2003;17:47–62.
11. Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. *J Clin Psychiatry* 2017;78:e264–78.
12. Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. *J Clin Psychiatry* 1993;54:133–9.
13. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. *Curr Opin Psychiatry* 2008;21:151–6.
14. Solmi M, Pigato G, Kane JM, Correll CU. Clinical risk factors for the development of tardive dyskinesia. *J Neurol Sci* 2018;389:21–7.
15. Correll CU, Kane JM, Citrome LL. Epidemiology, prevention, and assessment of tardive dyskinesia and advances in treatment. *J Clin Psychiatry* 2017;78:1136–47.
16. Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. *Schizophr Bull* 1992;18:701–15.
17. Woerner MG, Correll CU, Alvir JM, Greenwald B, Delman H, Kane JM. Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naïve patients. *Neuropsychopharmacology* 2011;36:1738–46.
18. Yassa R, Schwartz G. Depression as a predictor in the development of tardive dyskinesia. *Biol Psychiatry* 1984;19:441–4.
19. Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. *Arch Gen Psychiatry* 1993;50:723–33.
20. Tenback DE, van Harten PN, Slooff CJ, van Os J. Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study. *Am J Psychiatry* 2006;163:1438–40.
21. Jeste DV, Caligiuri MP, Paulsen JS, Heaton RK, Lacro JP, Harris MJ, et al. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. *Arch Gen Psychiatry* 1995;52:756–65.
22. Dixon L, Weiden PJ, Haas G, Sweeney J, Frances AJ. Increased tardive dyskinesia in alcohol-abusing schizophrenic patients. *Compr Psychiatry* 1992;33:121–2.
23. Potvin S, Blanchet P, Stip E. Substance abuse is associated with increased extrapyramidal symptoms in schizophrenia: a meta-analysis. *Schizophr Res* 2009;113:181–8.
24. Friedman JH. Tardive syndromes. *Continuum (Minneap Minn)* 2019;25:1081–98.
25. Savitt D, Jankovic J. Tardive syndromes. *J Neurol Sci* 2018;389:35–42.
26. Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? *Mov Disord* 2006;21:589–98.
27. Kane J, Woerner M, Weinhold P, Wegner J, Kinon B. A prospective study of tardive dyskinesia development: preliminary results. *J Clin Psychopharmacol* 1982;2:345.
28. Wonodi I, Adami HM, Cassidy SL, Sherr JD, Avila MT, Thaker GK. Ethnicity and the course of tardive dyskinesia in outpatients presenting to the motor disorders clinic at the Maryland psychiatric research center. *J Clin Psychopharmacol* 2004;24:592–8.
29. Glazer WM, Morgenstern H, Doucette JT. The prediction of chronic persistent versus intermittent tardive dyskinesia. A retrospective follow-up study. *Br J Psychiatry* 1991;158:822–8.
30. Gilbert PL, Harris MJ, McAdams LA, Jeste DV. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. *Arch Gen Psychiatry* 1995;52:173–88.
31. Evidence-based guideline: Treatment of tardive syndromes: report of the guideline development subcommittee of the American academy of neurology. *Neurology* 2013;81:1968.
32. Mentzel TQ, van der Snoek R, Lieveve R, Oorschot M, Viechtbauer W, Bloemen O, et al. Clozapine monotherapy as a treatment for antipsychotic-induced tardive dyskinesia: a meta-analysis. *J Clin Psychiatry* 2018;79.
33. Ricciardi L, Pringsheim T, Barnes TRE, Martino D, Gardner D, Remington G, et al. Treatment recommendations for tardive dyskinesia. *Can J Psychiatry* 2019;64:388–99.
34. Arya D, Khan T, Margolius AJ, Fernandez HH. Tardive dyskinesia: treatment update. *Curr Neurol Neurosci Rep* 2019;19:69.
35. Hazari N, Kate N, Grover S. Clozapine and tardive movement disorders: a review. *Asian J Psychiatr* 2013;6:439–51.
36. Conley RR, Kelly DL. Second-generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effects. *Isr J Psychiatry Relat Sci* 2005;42:51–60.
37. Niemann N, Jankovic J. Real-world experience with VMAT2 inhibitors. *Clin Neuropharmacol* 2019;42:37–41.
38. Bashir HH, Jankovic J. Treatment of tardive dyskinesia. *Neurologic Clinics* 2020;38:379–96.
39. Kazamatsuri H, Chien C, Cole JO. Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine. *Arch Gen Psychiatry* 1972;27:95–9.
40. O'Brien CF, Jimenez R, Hauser RA, Factor SA, Burke J, Mandri D, et al. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study. *Mov Disord* 2015;30:1681–7.
41. Factor SA, Remington G, Comella CL, Correll CU, Burke J, Jimenez R, et al. The effects of valbenazine in participants with tardive dyskinesia: results of the 1-Year KINECT 3 Extension Study. *J Clin Psychiatry* 2017;78:1344–50.
42. Fernandez HH, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, et al. Randomized controlled trial of deutetabenazine for tardive dyskinesia: the ARM-TD study. *Neurology* 2017;88:2003–10.
43. Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isojärvi J, et al. Deutetabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Psychiatry* 2017;4:595–604.
44. Bhidayasiri R, Jitkrisadukul O, Friedman JH, Fahn S. Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. *J Neurol Sci* 2018;389:67–75.
45. Pouclet-Courtemanche H, Rouaud T, Thobois S, Nguyen JM, Brefel-Courbon C, Chereau I, et al. Long-term efficacy and tolerability of bilateral pallidal stimulation to treat tardive dyskinesia. *Neurology* 2016;86:651–9.
46. Gruber D, Sudmeyer M, Deuschl G, Falk D, Krauss JK, Mueller J, et al. Neurostimulation in tardive dystonia/dyskinesia: a delayed start, sham stimulation-controlled randomized trial. *Brain Stimul* 2018;11:1368–77.
47. Adityanjee, Aderibigbe YA, Jampala VC, Mathews T. The current status of tardive dystonia. *Biol Psychiatry* 1999;45:715–30.
48. Macerollo A, Deuschl G. Deep brain stimulation for tardive syndromes: systematic review and meta-analysis. *J Neurol Sci* 2018;389:55–60.
49. Kiriakakis V, Bhatia KP, Quinn NP, Marsden CD. The natural history of tardive dystonia. A long-term follow-up study of 107 cases. *Brain* 1998;121(Pt 11):2053–66.
50. Van Putten T, Wirshing WC, Marder SR. Tardive Meige syndrome responsive to clozapine. *J Clin Psychopharmacol* 1990;10:381–2.
51. Wojcik JD, Falk WE, Fink JS, Cole JO, Gelenberg AJ. A review of 32 cases of tardive dystonia. *Am J Psychiatry* 1991;148:1055–9.
52. Tarsy D, Kaufman D, Sethi KD, Rivner MH, Molho E, Factor S. An open-label study of botulinum toxin A for treatment of tardive dystonia. *Clin Neuropharmacol* 1997;20:90–3.
53. Skidmore F, Reich SG. Tardive Dystonia. *Curr Treat Options Neurol* 2005;7:231–6.
54. Kang UJ, Burke RE, Fahn S. Natural history and treatment of tardive dystonia. *Mov Disord* 1986;1:193–208.
55. Sachdev P. The epidemiology of drug-induced akathisia: part ii. Chronic, tardive, and withdrawal akathisia. *Schizophr Bull* 1995;21:451–61.
56. Burke RE, Kang UJ, Jankovic J, Miller LG, Fahn S. Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. *Mov Disord* 1989;4:157–75.
57. Miller CH, Fleischhacker WW. Managing antipsychotic-induced acute and chronic akathisia. *Drug Saf* 2000;22:73–81.
58. Levin H, Chengappa KN, Kambhampati RK, Mahdavi N, Ganguli R. Should chronic treatment-refractory akathisia be an indication for the use of clozapine in schizophrenic patients? *J Clin Psychiatry* 1992;53:248–51.
59. Jiménez-Jiménez FJ, Puertas I, de Toledo-Heras M. Drug-induced myoclonus: frequency, mechanisms and management. *CNS Drugs* 2004;18:93–104.
60. Little JT, Jankovic J. Tardive myoclonus. *Mov Disord* 1987;2:307–11.
61. Fukuzako H, Tominaga H, Izumi K, Koja T, Nomoto M, Hokazono Y, et al. Postural myoclonus associated with long-term administration of neuroleptics in schizophrenic patients. *Biol Psychiatry* 1990;27:1116–26.
62. Fountoulakis KN, Samara M, Siaperla M, Iacovides A. Tardive Tourette-like syndrome: a systematic review. *Int Clin Psychopharmacol* 2011;26:237–42.
63. Lee MJ, Lin PY, Chang YY, Chong MY, Lee Y. Antipsychotics-induced tardive syndrome: a retrospective epidemiological study. *Clin Neuropharmacol* 2014;37:111–5.
64. Ford B, Greene P, Fahn S. Oral and genital tardive pain syndromes. *Neurology* 1994;44:2115–9.
65. Stacy M, Jankovic J. Tardive tremor. *Mov Disord* 1992;7:53–7.

66. Chiu H, Shum P, Lau J, Lam L, Lee S. Prevalence of tardive dyskinesia, tardive dystonia, and respiratory dyskinesia among Chinese psychiatric patients in Hong Kong. *Am J Psychiatry* 1992;149:1081–5.
67. Raja M. Tardive dystonia. Prevalence, risk factors, and comparison with tardive dyskinesia in a population of 200 acute psychiatric inpatients. *Eur Arch Psychiatry Clin Neurosci* 1995;245:145–51.
68. Sethi KD, Hess DC, Harp RJ. Prevalence of dystonia in veterans on chronic antipsychotic therapy. *Mov Disord* 1990;5:319–21.
69. Gibb WR, Lees AJ. The clinical phenomenon of akathisia. *J Neurol Neurosurg Psychiatry* 1986;49:861–6.
70. Sandyk R, Kay SR. Relationship of neuroleptic-induced akathisia to drug-induced parkinsonism. *Ital J Neurol Sci* 1990;11:439–42.
71. Orti-Pareja M, Jimenez-Jimenez FJ, Vazquez A, Catalan MJ, Zurdo M, Burguera JA, et al. Drug-induced tardive syndromes. *Parkinsonism Relat Disord* 1999;5:59–65.
72. Factor SA, Burkhard PR, Caroff S, Friedman JH, Marras C, Tinazzi M, et al. Recent developments in drug-induced movement disorders: a mixed picture. *Lancet Neurol* 2019;18:880–90.
73. Greene P. Baclofen in the treatment of dystonia. *Clin Neuropharmacol* 1992;15:276–88.